[1] Bogoch II, Watts A, Thomas-Bachli A, et al. Potential for global spread of a novel coronavirus from China[J].J Travel Med,2020,27(2):taaa011.DOI:10.1093/jtm/taaa011.
[2] Baala L, Benzekri-Lefevre D, Bret L, et al. Case Report: Co-infection with SARS-CoV-2 and influenza H1N1 in a patient with acute respiratory distress syndrome and a pulmonary sarcoidosis[J].F1000Res,2020,9:1482.DOI:10.12688/f1000research.26924.2.
[3] Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J].Lancet,2020,395(10223):514-523.DOI:10.1016/S0140-6736(20)30154-9.
[4] Jamil S, Mark N, Carlos G, et al. Diagnosis and management of COVID-19 disease[J].Am J Respir Crit Care Med,2020,201(10):P19-P20.DOI:10.1164/rccm. 2020C1.
[5] 王江,徐轶,陈俊峰,等. 流感病毒实验室检测方法研究进展[J]. 中华医院感染学杂志,2020,30(2):308-312. DOI:10.11816/cn.ni.2020-191003.
[6] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL](2022-03-15).http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.
[7] 中华人民共和国国家卫生健康委员会,国家中医药管理局. 流行性感冒诊疗方案(2020年版)[J]. 中华临床感染病杂志,2020,13(6):401-405,411.DOI:10.3760/cma.j.issn.1674-2397.2020.06.001.
[8] Luo Y, Yuan X, Xue Y, et al. Using a diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus[J].Int J Infect Dis,2020,95:436-440.DOI:10.1016/j.ijid.2020.04.078.
[9] Leung EC, Chow VC, Lee MK, et al. Evaluation of the Xpert Xpress SARS-CoV-2/Flu/RSV assay for simultaneous detection of SARS-CoV-2, influenza A and B viruses, and respiratory syncytial virus in nasopharyngeal specimens[J].J Clin Microbiol,2021,59(4):e02965.DOI:10.1128/JCM.02965-20.
[10] 刘晓庆,张闰,何广胜. 新型冠状病毒感染后血液细胞学指标变化——疾病诊断和发展的预警[J]. 中国实用内科杂志,2020,40(6):461-465.DOI:10.19538/j.nk2020060105.
[11] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J].Lancet,2020,395(10223):497-506.DOI:10.1016/S0140-6736(20)30183-5.
[12] Peng J, Qi D, Yuan G, et al. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): a multicenter, cross-sectional study[J].J Clin Lab Anal,2020,34(10):e23475.DOI:10.1002/jcla.23475.
[13] Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis[J].J Med Virol,2020,92(10):1733-1734.DOI:10.1002/jmv.25819.
[14] Damar Çakırca T, Torun A, Çakırca G, et al. Role of NLR, PLR, ELR and CLR in differentiating COVID-19 patients with and without pneumonia[J].Int J Clin Pract,2021,75(11):e14781.DOI:10.1111/ijcp.14781.
[15] Jones JE, Le Sage V, Padovani GH, et al. Parallel evolution between genomic segments of seasonal human influenza viruses reveals RNA-RNA relationships[J].Elife,2021,10:e66525.DOI:10.7554/eLife.66525.
[16] 曹义,胡伟强,李金玉,等. 外周血CRP、NLR、PLR、LMR检测在甲/乙型流感患者中的临床应用[J]. 国际医药卫生导报,2020,26(24):3816-3819.DOI:10.3760/cma.j.issn.1007-1245.2020.24.027.
[17] Yang AP, Liu JP, Tao WQ, et al. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients[J].Int Immunopharmacol,2020,84:106504.DOI:10.1016/j.intimp.2020.106504.
[18] Prozan L, Shusterman E, Ablin J, et al. Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection[J].Sci Rep,2021,11(1):21519.DOI:10.1038/s41598-021-00927-x.
|